Jade Biosciences, Inc.

JBIO

$16.76

Updated: 22/09/2026, 21:31:11

Market Cap

$1.02B

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for JBIO

Company Profile

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

USD

NASDAQ

CEO: Tom Frohlich

Employees: 55

https://jadebiosciences.com

Asset Summaries

Latest generated summaries for JBIO

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for JBIO.

Share price: $16.76
Market cap: $1.02B
Exchange: NASDAQ
Currency: USD
CEO: Tom Frohlich
Employees: 55
IPO date: 30/06/2021
Beta: 1.454
Last dividend: $0.00
Day range: $16.60 – $17.16
52-week range: $7.30 – $28.00
1-day performance: 0.15%
1-year performance: 129.71%
Current drawdown (1Y): -40.13%
CIK: 0001798749
CUSIP: 008064206
ISIN: US0080642061
Created: 07/12/2025, 04:50:13
Last update: 22/09/2026, 21:31:11

Track Jade Biosciences, Inc. with an AI analyst

See which prediction-market events move JBIO, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to JBIO from your Railway `news_articles` table.

Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewsWire • STOCK • 05/06/2026, 18:01:00

Jade Biosciences Announces Pricing of Public Offering of Common Stock

Globe News Wire • STOCK • 04/06/2026, 00:58:04

Jade Biosciences Announces Pricing of Public Offering of Common Stock

GlobeNewsWire • STOCK • 04/06/2026, 00:58:00

Jade Biosciences Announces Proposed Underwritten Public Offering

GlobeNewsWire • STOCK • 03/06/2026, 18:01:00

Jade Biosciences' JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials

MarketBeat • STOCK • 01/06/2026, 23:08:09

Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans Transcript

Seeking Alpha • STOCK • 01/06/2026, 18:44:11

Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy

GlobeNewsWire • STOCK • 29/05/2026, 18:05:00

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

GlobeNewsWire • STOCK • 06/03/2026, 08:00:00